...ting medium is specifically formulated for mountin...ch have been stained with immunohistochemical meth...or use with chromogens, such as AEC, that are alco... Faramount dries completely when slides are cover-...
...trieval Solution, High pH This pH 9.9 solution is...to immunohistochemical staining procedures. It is ...e sections mounted on glass slides. For particular...pecially effective. It should be noted that also e...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) from Dako
Mouse Anti-Yersinia pestis F1 Antigen EB Strain Monoclonal Antibody, Unconjugated, Clone YPF19 from Meridian Life Science, Inc.
Biology Products:(Date:11/4/2009)...RLSBAD, Calif., Oct. 23 GenVault C...ample management for genomic discovery, medicine a...is, Ph.D., GenVault,s President and CEO, will be p... place on October 26th and 27th in La Jolla, CA. ,...ide an overview of the company together with recen...
(Date:11/4/2009)... CHAPEL HILL Scientists at the University of Nort...he University of California, San Francisco have de...redict new target diseases for existing drugs. , ...that compares how similar the structures of all kn...artners -- known as ligands -- of disease targets ...
(Date:11/3/2009)...ON, WI, NOVEMBER 4, 2009 -- The world,s greatest ...grape variety, human input, and something called t...rd site, soil, and climate. , Experts will dis... symposium on Wednesday, Nov. 4 in Pittsburgh. "T...esented in two parts at the 2009 Annual Meetings o...
Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Study points to new uses, unexpected side effects of already existing drugs 2Great wines come from great soils 2Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 1Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 2Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 3Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 4Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 5Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 6Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 7Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 8HPV Vaccine Could Prevent Many Penile Cancers 55330 1HPV Vaccine Could Prevent Many Penile Cancers 55330 2Frank Sadeghi Joins CBCA Administrators Inc as Executive Vice President of Business Development 55326 1Frank Sadeghi Joins CBCA Administrators Inc as Executive Vice President of Business Development 55326 2(Date:11/5/2009)...RG, Md., Nov. 5 GenVec, ...l results for the third quarter ended September 30... ($0.04 per share) for the three months ended Sept...ion ($0.08 per share) in the comparable quarter of...9, GenVec,s net loss was $14.1 million ($0.15 per ...
(Date:11/5/2009)... Nov. 5 Imagenetix, Inc....William Spencer, President and CEO of Imagenetix, ...annual LD MICRO Conference on Thursday, December 3...les. ,, About LD MICRO ,, LD MICRO is a by-i...ding undervalued companies in the micro-cap space....
(Date:11/5/2009)...., Nov. 5 Transgenomic, ...nancial results for the quarter ended September 30...ted in the tables that follow. ,, Third Quarte...366,000 or $0.01 per share for the third quarter o....01 per share for the third quarter of 2008. ,...
(Date:11/5/2009)..., Texas, Nov. 5 Wound Ma...ay that it has entered into a Letter of Intent to ...Health Technologies, Inc. (OTC Bulletin Board: VHG...00 in cash and debt, 4,000,000 shares of WNDM and ... on the Veriscrip technology being acquired from V...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3